2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 248

Hand Osteoarthritis Is Associated With Increased Type II Collagen Degradation In Women: The Ofely Study
Abstract Number: 164

Haptoglobin Chains As Potential Biomarkers In Serum Of Osteoarthritis Disease
Abstract Number: 378

HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up
Abstract Number: 2326

Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
Abstract Number: 1997

Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study
Abstract Number: 873

Health Fair Evaluations To Identify Subjects At-Risk For Future Inflammatory Arthritis and Rheumatoid Arthritis
Abstract Number: 1031

Health Literacy Predicts Discrepancies Between Traditional Written Rheumatoid Arthritis Patient Assessments and Verbally-Administered Assessments
Abstract Number: 329

Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry
Abstract Number: 2018

Hemophagocytic Lymphohistiocytosis As a Clinical Syndrome Of Autoimmune Diseases, Haematology, Oncology and Infectious Diseases
Abstract Number: 2634

Henoch-Schönlein Purpura: Clinical Spectrum Of The Disease In 417 Patients From A Single Center
Abstract Number: 67

Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) As a Potential Mediator In Osteoarthritis
Abstract Number: 1408

High Body Mass Index Is Associated With a Reduced Long Term Risk Of Rheumatoid Arthritis In Men
Abstract Number: 749

High Clinical Remission Rate With Relatively High Incidence Of Serious Infection In Newly-Onset ANCA-Associated Vasculitides In Japan – A Report From The Nationwide Prospective Cohort Study
Abstract Number: 1703

High Density Genotyping Of Immune-Related Disease Genes Identifies 7 New Susceptibility Loci For Behçet’s Disease
Abstract Number: 2736

High Density Microarray Analysis Identifies Novel Differentially Expressed Long Noncoding RNAs In Rheumatoid Arthritis Synovial Fibroblasts

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].